Real-world effectiveness and safety of belumosudil in pediatric refractory chronic graft-versus-host disease

Wobma H, Kapadia M, Kim HT, Alvarez-Calderon F, Baumeister SHC, Duncan C, et al. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023;7:4647–57.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Carpenter PA, Kang HJ, Yoo KH, Zecca M, Cho B, Lucchini G, et al. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study. Transpl Cell Ther. 2022;28:771 e771–771 e710.

Google Scholar 

Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Wang Y, Wu D, Zhang X, Li Y, He Y, Liu Q, et al. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China. BMC Med. 2024;22:142.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Leukemia Expert Committee of the Chinese Society of Clinical OncologyGuidelines on the clinical application of belumosudil mesylate for the treatment of chronic graft-versus-host disease (2024 edition). Leukemia Lymphoma. 2024;33:385–91.

Google Scholar 

Lee SJ, Pavletic S, Blazar BR, Yao Y, Ji R, Marshall K, et al. Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies. Transpl Cell Ther. 2025;31:434.e431–434.e410.

Google Scholar 

Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transpl. 2015;21:984–99.

Article 

Google Scholar 

Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018;103:1535–41.

Article 
PubMed 
PubMed Central 

Google Scholar 

Chen W, Wang Z, Liu Z, Fu B, Xing T, You J, et al. Belumosudil in pediatric patients with chronic graft-versus-host disease after failed multi-line therapy: a case series. Ann Hematol. 2025;104:1241–7.

Article 
CAS 
PubMed 

Google Scholar 

Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, et al. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Lancet Haematol. 2024;11:e580–e592.

Article 
CAS 
PubMed 

Google Scholar 

Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2014;20:337–44.

Article 

Google Scholar